Sanofi snaps up acne vaccine developer Origimm BioSanofi has added to its vaccine pipeline with an agreement to acquire Austria’s Origimm Biotechnology and its vaccine-based Share XSanofi snaps up acne vaccine developer Origimm Biohttps://pharmaphorum.com/news/sanofi-snaps-up-acne-vaccine-developer-origimm-bio/
Novartis may have found a buyer for Sandoz; reportJust a few weeks after Novartis revealed it was considering a sale of its generics business Sandoz, there Share XNovartis may have found a buyer for Sandoz; reporthttps://pharmaphorum.com/news/novartis-may-have-found-a-buyer-for-sandoz-report/
Vifor builds in kidney disease with Sanifit, Inositec buysOn the heels of a late-stage clinical trial failure, Vifor Pharma has moved to bolster its pipeline by Share XVifor builds in kidney disease with Sanifit, Inositec buyshttps://pharmaphorum.com/news/vifor-builds-in-kidney-disease-with-sanifit-inositec-buys/
Is digital health giant Athenahealth heading for new ownership?In 2018, the takeover of Athenahealth by Veritas Capital and Elliott Management for $5.5 billion was the biggest Share XIs digital health giant Athenahealth heading for new ownership?https://pharmaphorum.com/news/is-digital-health-giant-athenahealth-heading-for-new-ownership/
Novo Nordisk snaps up RNAi partner Dicerna in $3.3bn takeover dealDanish drugmaker Novo Nordisk must like what it has seen in its two-year-old alliance with gene-silencing specialist Dicerna Share XNovo Nordisk snaps up RNAi partner Dicerna in $3.3bn takeover dealhttps://pharmaphorum.com/news/novo-nordisk-snaps-up-rnai-partner-dicerna-in-3-3bn-takeover-deal/
J&J finally decides to dismantle its diversified business modelAfter decades of a diversified healthcare business model, Johnson & Johnson has announced it plans to split off Share XJ&J finally decides to dismantle its diversified business modelhttps://pharmaphorum.com/news/jj-finally-decides-to-dismantle-its-diversified-business-model/
Swiss socialists say government should buy SandozSwitzerland’s Social Democratic Party has argued that the government should step in and acquire Novartis’ generics unit Sandoz Share XSwiss socialists say government should buy Sandozhttps://pharmaphorum.com/news/swiss-socialists-say-government-should-buy-sandoz/
Novartis finally sells Roche stake, for almost $21 billionAfter more than 20 years, Novartis has finally decided to sell its substantial share in fellow Swiss pharma Share XNovartis finally sells Roche stake, for almost $21 billionhttps://pharmaphorum.com/news/novartis-finally-sells-roche-stake-for-almost-21-billion/
Takeda buys GammaDelta to boost cancer cell therapy credentialsJapanese drugmaker Takeda has said it will exercise its option to buy UK-based GammaDelta Therapeutics, a specialist in Share XTakeda buys GammaDelta to boost cancer cell therapy credentialshttps://pharmaphorum.com/news/takeda-buys-gammadelta-to-boost-cancer-cell-therapy-credentials/
